201 related articles for article (PubMed ID: 27984757)
41. Balance of IL-10 and interferon-gamma plasma levels in human visceral leishmaniasis: implications in the pathogenesis.
Caldas A; Favali C; Aquino D; Vinhas V; van Weyenbergh J; Brodskyn C; Costa J; Barral-Netto M; Barral A
BMC Infect Dis; 2005 Dec; 5():113. PubMed ID: 16364177
[TBL] [Abstract][Full Text] [Related]
42. Interleukin-12 augments a Th1-type immune response manifested as lymphocyte proliferation and interferon gamma production in Leishmania infantum-infected dogs.
Strauss-Ayali D; Baneth G; Shor S; Okano F; Jaffe CL
Int J Parasitol; 2005 Jan; 35(1):63-73. PubMed ID: 15619517
[TBL] [Abstract][Full Text] [Related]
43. Antineoplastic drug, carboplatin, protects mice against visceral leishmaniasis.
Kaur T; Makkar P; Randhawa K; Kaur S
Parasitol Res; 2013 Jan; 112(1):91-100. PubMed ID: 22961311
[TBL] [Abstract][Full Text] [Related]
44. Study the effects of PLGA-PEG encapsulated amphotericin B nanoparticle drug delivery system against Leishmania donovani.
Kumar R; Sahoo GC; Pandey K; Das V; Das P
Drug Deliv; 2015 May; 22(3):383-8. PubMed ID: 24601828
[TBL] [Abstract][Full Text] [Related]
45. Histamine H1-receptor antagonists against Leishmania (L.) infantum: an in vitro and in vivo evaluation using phosphatidylserine-liposomes.
Pinto EG; da Costa-Silva TA; Tempone AG
Acta Trop; 2014 Sep; 137():206-10. PubMed ID: 24905294
[TBL] [Abstract][Full Text] [Related]
46. Influence of the vehicle on the properties and efficacy of microparticles containing amphotericin B.
Sánchez-Brunete JA; Dea MA; Rama S; Bolás F; Alunda JM; Torrado-Santiago S; Torrado JJ
J Drug Target; 2005 May; 13(4):225-33. PubMed ID: 16051534
[TBL] [Abstract][Full Text] [Related]
47. Efficacy and tolerability of oleylphosphocholine (OlPC) in a laboratory model of visceral leishmaniasis.
Fortin A; Hendrickx S; Yardley V; Cos P; Jansen H; Maes L
J Antimicrob Chemother; 2012 Nov; 67(11):2707-12. PubMed ID: 22782488
[TBL] [Abstract][Full Text] [Related]
48. Targeting of mannosylated liposome incorporated benzyl derivative of Penicillium nigricans derived compound MT81 to reticuloendothelial systems for the treatment of visceral leishmaniasis.
Mitra M; Mandal AK; Chatterjee TK; Das N
J Drug Target; 2005 Jun; 13(5):285-93. PubMed ID: 16199372
[TBL] [Abstract][Full Text] [Related]
49. [Experimental visceral leishmaniasis in golden hamsters].
Shukina EE; Gorbunova LA
Parazitologiia; 1987; 21(5):637-42. PubMed ID: 3431905
[TBL] [Abstract][Full Text] [Related]
50. Stereological analysis of liver, spleen and bone of Leishmania infantum-experimentally infected hamsters.
Modabberi F; Ghadimi SN; Shahriarirad R; Nadimi E; Karbalay-Doust S; Rashidi S; Sarkari B
Exp Parasitol; 2021 Sep; 228():108137. PubMed ID: 34298076
[TBL] [Abstract][Full Text] [Related]
51. Prophylactic or therapeutic administration of Agaricus blazei Murill is effective in treatment of murine visceral leishmaniasis.
Valadares DG; Duarte MC; Ramírez L; Chávez-Fumagalli MA; Martins VT; Costa LE; Lage PS; Ribeiro TG; Castilho RO; Fernandes AP; Régis WC; Soto M; Tavares CA; Coelho EA
Exp Parasitol; 2012 Oct; 132(2):228-36. PubMed ID: 22824583
[TBL] [Abstract][Full Text] [Related]
52. Liposomal resiquimod for the treatment of Leishmania donovani infection.
Peine KJ; Gupta G; Brackman DJ; Papenfuss TL; Ainslie KM; Satoskar AR; Bachelder EM
J Antimicrob Chemother; 2014 Jan; 69(1):168-75. PubMed ID: 23956375
[TBL] [Abstract][Full Text] [Related]
53. Self assembled ionically sodium alginate cross-linked amphotericin B encapsulated glycol chitosan stearate nanoparticles: applicability in better chemotherapy and non-toxic delivery in visceral leishmaniasis.
Gupta PK; Jaiswal AK; Asthana S; Verma A; Kumar V; Shukla P; Dwivedi P; Dube A; Mishra PR
Pharm Res; 2015 May; 32(5):1727-40. PubMed ID: 25425053
[TBL] [Abstract][Full Text] [Related]
54. Verification and monitoring of visceral leishmaniasis in hamsters caused by Leishmania infantum, using non-invasive approaches involving ultrasound imaging and blood gases.
Murillo J; Montoya A; Carrillo-Bonilla L; Rodriguez B; Vélez ID; Robledo SM
Exp Parasitol; 2019 Jun; 201():78-89. PubMed ID: 31047987
[TBL] [Abstract][Full Text] [Related]
55. Targeting of piperine intercalated in mannose-coated liposomes in experimental leishmaniasis.
Raay B; Medda S; Mukhopadhyay S; Basu MK
Indian J Biochem Biophys; 1999 Aug; 36(4):248-51. PubMed ID: 10650726
[TBL] [Abstract][Full Text] [Related]
56. An optimized nanoparticle delivery system based on chitosan and chondroitin sulfate molecules reduces the toxicity of amphotericin B and is effective in treating tegumentary leishmaniasis.
Ribeiro TG; Franca JR; Fuscaldi LL; Santos ML; Duarte MC; Lage PS; Martins VT; Costa LE; Fernandes SO; Cardoso VN; Castilho RO; Soto M; Tavares CA; Faraco AA; Coelho EA; Chávez-Fumagalli MA
Int J Nanomedicine; 2014; 9():5341-53. PubMed ID: 25429219
[TBL] [Abstract][Full Text] [Related]
57. Activity of liposomal amphotericin B (AmBisome) against Leishmania infantum and tissue distribution in mice.
Gradoni L; Davidson RN; Orsini S; Betto P; Giambenedetti M
J Drug Target; 1993; 1(4):311-6. PubMed ID: 8069573
[TBL] [Abstract][Full Text] [Related]
58. Oral miltefosine for Indian visceral leishmaniasis.
Sundar S; Jha TK; Thakur CP; Engel J; Sindermann H; Fischer C; Junge K; Bryceson A; Berman J
N Engl J Med; 2002 Nov; 347(22):1739-46. PubMed ID: 12456849
[TBL] [Abstract][Full Text] [Related]
59. Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial.
Sundar S; Sinha PK; Rai M; Verma DK; Nawin K; Alam S; Chakravarty J; Vaillant M; Verma N; Pandey K; Kumari P; Lal CS; Arora R; Sharma B; Ellis S; Strub-Wourgaft N; Balasegaram M; Olliaro P; Das P; Modabber F
Lancet; 2011 Feb; 377(9764):477-86. PubMed ID: 21255828
[TBL] [Abstract][Full Text] [Related]
60. An effective in vitro and in vivo antileishmanial activity and mechanism of action of 8-hydroxyquinoline against Leishmania species causing visceral and tegumentary leishmaniasis.
Costa Duarte M; dos Reis Lage LM; Lage DP; Mesquita JT; Salles BC; Lavorato SN; Menezes-Souza D; Roatt BM; Alves RJ; Tavares CA; Tempone AG; Coelho EA
Vet Parasitol; 2016 Feb; 217():81-8. PubMed ID: 26827866
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
